Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27

Hui Chen Pai1, Sunil Kumar2, Chien-Chang Shen3

  • 1Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan.

Plos One
|April 16, 2015
PubMed
Abstract

Insights

MT-4, a moscatilin derivative, effectively inhibits growth in sensitive and multidrug-resistant ovarian cancer cells by inducing apoptosis. This compound shows potential as a lead for treating resistant ovarian cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer remains a significant health challenge, particularly cases resistant to conventional chemotherapy.
  • Multidrug resistance (MDR) in ovarian cancer limits treatment efficacy and necessitates novel therapeutic strategies.
  • Understanding the molecular mechanisms underlying drug resistance is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the anticancer mechanisms of MT-4, a moscatilin derivative, in both sensitive and multidrug-resistant human ovarian cancer cell lines.
  • To evaluate the potential of MT-4 as a therapeutic agent for ovarian cancer, including MDR cases.

Main Methods:

  • In vitro assays: cell viability, cell cycle analysis, tubulin polymerization assay, and immunoblotting.
  • In vivo xenograft assays to assess efficacy in a living organism.
  • Investigation of MT-4's interaction with P-glycoprotein (P-gp) and its effect on key cell cycle and apoptosis-related proteins.

Main Results:

  • MT-4 demonstrated significant inhibition of cell growth and viability in both A2780 (sensitive) and NCI-ADR/res (multidrug-resistant) ovarian cancer cells.
  • MT-4 induced G2/M cell cycle arrest and subsequent caspase-mediated apoptosis by inhibiting tubulin polymerization.
  • The compound is not a substrate of P-glycoprotein, suggesting it can overcome P-gp-mediated resistance.
  • MT-4 modulated key proteins involved in cell cycle progression (cyclin B, Cdc2/p34, PLK1, Aurora kinase B, histone H3) and apoptosis.
  • Activation of the p38 MAPK pathway and regulation of heat shock protein 27 (HSP27) were identified as critical components of MT-4-induced apoptosis, impacting chemotherapy resistance.

Conclusions:

  • MT-4 exhibits potent anticancer activity against sensitive and multidrug-resistant ovarian cancer cells through mechanisms involving tubulin polymerization inhibition, G2/M arrest, and apoptosis induction.
  • MT-4's efficacy is mediated by the p38 MAPK pathway and modulation of HSP27, suggesting a novel approach to overcoming chemotherapy resistance.
  • These findings highlight MT-4 as a promising lead compound for the development of new therapies for multidrug-resistant ovarian cancer.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

8.0K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K